Quetiapine-induced hyperprolactinemic galactorrhea in an adolescent male

German Journal of Psychiatry

Volumn 9, Issue 3, 2006, Pages 118-120

  Buhagiar, Kurt ^a   Cassar, Joseph R ^a  

^a Mount Carmel Hospital   (Malta)

Author keywords

Atypical antipsychotic; Galactorrhoea; Hyperprolactinemia; Quetiapine

Indexed keywords

PROLACTIN; QUETIAPINE;

ACADEMIC ACHIEVEMENT; ADOLESCENT; AGGRESSIVENESS; ARTICLE; BEHAVIOR THERAPY; BREAST DISCHARGE; CASE REPORT; CONDUCT DISORDER; DISRUPTIVE BEHAVIOR; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; GALACTORRHEA; HOSPITALIZATION; HUMAN; HYPERPROLACTINEMIA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPOSITIONAL DEFIANT DISORDER; PROLACTIN BLOOD LEVEL;

EID: 33747005566     PISSN: 14331055     EISSN: 14331055     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Alfaro CL, Wudarsky M, Nicolson R, Gochman P, Sporn A, Lenane M, Rapoport JL. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol 2002; 12: 83-91.
2. Cesena M, Gonzalez-Heydrich J, Szigethy E, Kohlenberg TM, DeMaso DR. A case series of eight aggressive young children treated with risperidone. J Child Adolesc Psychopharmacol 2001; 12: 337-345.
3. De Borja Gonçalves Guerra A, Castel S, Benedito-Silva AA, Calil HM. Neuroendocrine effects of quetiapine in healthy volunteers. Int J Neuropsychopharmacol 2005; 8: 49-57.
4. Dickson RA, Seeman MV, Corenblum B. Hormonal side effects in women: typical versus atypical antipsychotic treatment. J Clin Psychiatry 2000; 61 Suppl 3: 10-5.
5. Findling RL, McNamara NK, Gracious BL. Pediatric uses of atypical antipsychotics. Expert Opin Pharmacother 2000; 1935-45.
6. Findling RL. Use of quetiapine in children and adolescents. J Child Adolesc Psychopharmacol 2004; 14:287-94.
7. Frazier JA, Meyer MC, Biederman J, Wozniak J, Wilens TE, Spencer TJ, Kim GS, Shapiro S. Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. J Am Acad Child Adolesc Psychiatry 1999; 38: 960-5.
8. Garver DL. Review of quetiapine side effects. J Clin Psychiatry 2000; 61 Suppl 8: 31-3.
9. Hardan A, Johnson K, Johnson C. Case Study: Risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry 1996; 35; 1551-1556.
10. Hardan AY, Jou RJ, Handen BL. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord 2005; 35: 387-91.
11. Kapur X, Langlois P, Vinken A, Megens AHP, De Coster R, Andrews JS. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 2002; 302: 1129-1134.
12. Marchand WR, Wirth L, Simon C. Quetiapine adjunctive and monotherapy for pediatric bipolar disorder: a retrospective chart review. J Child Adolesc Psychopharmacol 2004; 14: 405-11.
13. Masi G, Cosenza A, Mucci M. Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharmacol 2001; 11: 389-394.
14. McConville BJ, Arvanitis LA, Thyrum PT, Yeh C, Wilkinson LA, Chaney RO, Foster KD, Sorter MT, Friedman LM, Brown KL, Heubi JE. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000; 61: 252-60.
15. Párraga HC, Párraga MI, Woodward RL, Fenning PA. Quetiapine treatment of children with Tourette's syndrome: report of two cases. J Child Adolesc Psychopharmacol 2001; 11: 187-91.
16. Saito E, Correll CU, Gallelli K, McMeniman M, Parikh UH, Malhotra AK, Kafantaris AK. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol 2004; 14: 350-358.
17. Small JG, Hirsch RS, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high-and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54:549-557.
18. Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R, Pupo-Guillen M. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 2001; 11: 415-424.
19. Stanniland C, Taylor D. Tolerability of Atypical Antipsychotics. Drug Saf 2000; 22: 195-214.
20. Stevens JR, Kymissis PI, Baker AJL. Elevated prolactin in male youth treated with risperidone and quetiapine. Child Adolesc Psychopharm 2005; 15: 893-900.
21. Toren P, Ratner S, Laor N, Weizman A. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Saf 2004; 27: 1135-1156.
22. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinemia in women: pathophysiology, severity and consequences. Br J Psychiatry 2003; 182: 199-204.